Introduction
============

Leber hereditary optic neuropathy (LHON; OMIM [\#535000](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=535000)) is a common cause of inherited blindness that typically presents with bilateral, painless, subacute vision failure in young adult males. Affected individuals develop focal degeneration of the optic nerve and present clinically with impaired color vision (dyschromatopsia), a dense visual field defect (central or cecocentral scotoma), and abnormal visual electrophysiology due to primary retinal ganglion cell loss \[[@r1]\]. The diagnosis is usually confirmed by molecular genetic analysis for one of three common mitochondrial DNA (mtDNA) mutations which all affect genes coding for complex I subunits of the respiratory chain: m.3460G\>A, m.11778G\>A, and m14484T\>C. However, only a few patients harboring a pathogenic LHON mtDNA mutation develop visual failure \[[@r2],[@r3]\]. Segregation analysis of LHON pedigrees indicated a two-locus model: a mtDNA mutation as one locus and a modulating X-chromosomal locus \[[@r4]\]. Although an interacting X-chromosomal locus could explain the gender bias in LHON, not all pedigrees with LHON show linkage to the X-chromosome \[[@r5]-[@r7]\], and the segregation pattern in some pedigrees implicates one or more autosomal loci \[[@r8]\]. However, attempts to identify a nuclear modifying gene by both genetic mapping and functional genomics have so far failed to identify the interacting nuclear genes.

Folate is a necessary component for cellular maintenance and growth, especially important during early embryonic development, where it is involved in DNA synthesis. Methylenetetrahydrofolate reductase (*MTHFR*) catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a critical step in the remethylation of homocysteine (Hcy) to methionine. Genetic variants in *MTHFR* are associated with hyperhomocysteinemia and cardiovascular disease \[[@r9]\] and are also associated with neural tube defects in the fetus \[[@r10]\]. c.677C\>T, present at approximately 33%--37% heterozygously and roughly 10% homozygously in Europeans, leads to a substitution of alanine to valine (at position 222) in the catalytic domain of MTHFR, and subsequent reduction in enzyme activity \[[@r11]\]. This effect is magnified when c.677C\>T is found as a compound heterozygote with homozygous c.1298A\>C \[[@r12],[@r13]\].

Previous studies have shown a link between oxidative stress and increased Hcy in neurodegenerative disorders \[[@r14],[@r15]\], with a pronounced increase in Hcy in homozygote c.677C\>T Alzheimer disease \[[@r16]\] and Parkinson disease \[[@r17]\]. Elevated levels of Hcy have been shown to cause endothelial dysfunction by increasing oxidative stress or impairing nitric oxide metabolism \[[@r18],[@r19]\]. Increased Hcy was shown to induce apoptotic death in retinal ganglion cells, hypothesized as a cause of LHON \[[@r20]\], by overstimulation of the N-methyl-D-aspartate receptors and caspase-3 activation \[[@r21]\].

Increased Hcy, but not the c.677C\>T variation, was identified as a risk factor in nonarteritic ischemic optic neuropathy and central retinal vein occlusion \[[@r22],[@r23]\]. Folate deficiency is known to cause bilateral optic neuropathy \[[@r24],[@r25]\]. Evidence is accumulating that implicates folate metabolism in optic neuropathies, particularly those affecting the retinal ganglion cell, making *MTHFR* a strong autosomal candidate genetic modifier in LHON, despite not localizing to the X chromosome and therefore less likely to contribute directly to the gender bias in LHON.

Methods
=======

We studied 12 common nonsynonymous *MTHFR* ([NM_005957.3](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=87239999)) single nucleotide polymorphisms (SNPs): ([rs2066472](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2066472), [rs45550133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45550133), [rs45438591](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45438591), [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736), [rs45496998](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45496998), [rs45449298](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45449298), [rs2274974](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274974), [rs45590836](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45590836), [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976), [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219), [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133), and [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131)) in a European cohort of 414 LHON mtDNA mutation carriers (182 affected, 232 unaffected). All subjects were recruited from two European centers with local ethical review board approval in accordance with the declaration of Helsinki. 70% of the attached individuals were male, and 41% of the unaffected individuals were male, in keeping with the gender bias that characterizes LHON. All were homoplasmic for m.3460G\>A, m.11778G\>A, or m14484T\>C. [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133) corresponds to c.677C\>T, and [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131) corresponds to c.1298A\>C. The additional ten SNPs were selected using the following criteria: 1) nonsynonymous substitutions predicted to affect *MTHFR* function; and 2) present in control subjects at \>0.1% ([dbSNP](http://www.ncbi.nlm.nih.gov/SNP/index.html)) \[[@r26]\].

The clinical phenotype was determined by a local ophthalmologist \[[@r1]\] and the genetic diagnosis was confirmed in affected individuals by mtDNA direct sequencing of the *MTND* genes or PCR-RFLP analysis. Control participants (unaffected mutation carriers) had no visual symptoms and were older (\>30 years) than the median age of onset for LHON (24 years). The frequency of sequence variants was determined in European controls by primer extension of multiplex polymerase chain reaction products with the detection of the allele-specific extension products by matrix-associated laser desorption/ionization time of flight (MALDITOF; Sequenom, San Diego, CA) mass spectrometry. Genotype and allelic associations were compared using SPSS v15.0 using Fishers exact test. The p values given are two-tailed. To correct for multiple testing bias, we performed permutation testing using [Haploview 4.0](http://www.broad.mit.edu/mpg/haploview). Statistical power calculation is available at [DSS research](http://www.dssresearch.com/toolkit/spcalc).

Results
=======

We analyzed SNP frequencies in 12 non-synonymous SNPs in a large LHON cohort. Six of the SNPs ([rs2066472](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2066472), [rs45550133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45550133), [rs45496998](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45496998), [rs45449298](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45449298), [rs2274974](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274974), and [rs45590836](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45590836)) showed no variation and were removed from any further analysis. When males and females were considered together, Fisher exact test revealed a weak association between [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976) and LHON ([Table 1](#t1){ref-type="table"}, p=0.030). When males and females were considered separately ([Table 2](#t2){ref-type="table"}), [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219) was associated with visual failure in male LHON patients (p=0.043), When different LHON mutations were studied separately, we observed a significant association between [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736) and both m.3460 G\>A and m.14484T\>C ([Table 3](#t3){ref-type="table"}, p=0.018 and 0.028 respectively). However none of these associations were significant after correcting for multiple testing bias using permutation testing.

###### Non-synonymous *MTHFR* variants in LHON.

  **Genotype frequency**                                                  **Patients**   **WT**   **Het**   **MT**   **P**
  ----------------------------------------------------------------------- -------------- -------- --------- -------- -------
  [rs45438591](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45438591)   A              173      8         0        0.323
  C                                                                       222            6        0                  
  [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)     A              113      56        13       0.479
  C                                                                       151            60       21                 
  [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736)   A              127      50        3        0.585
  C                                                                       172            54       3                  
  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131)     A              81       78        23       0.143
  C                                                                       112            102      16                 
  [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976)     A              151      25        5        0.104
  C                                                                       207            19       3                  
  [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219)   A              177      2         3        0.171
  C                                                                       221            9        2                  
  **Allele frequency**                                                    **Patients**   **WT**   **MT**    **P**    
  [rs45438591](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45438591)   A              354      8         0.2854   
  C                                                                       450            6                           
  [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)     A              282      82        0.867    
  C                                                                       362            102                         
  [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736)   A              304      56        0.364    
  C                                                                       398            60                          
  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131)     A              240      124       0.131    
  C                                                                       326            134                         
  [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976)     A              327      35        0.03     
  C                                                                       433            25                          
  [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219)   A              356      8         0.66     
  C                                                                       451            13                          

Comparison of *MTHFR* variant genotype and allele frequencies between LHON patients (A) and controls (C; where WT and MT are homozygous wild-type and mutant, respectively and Het is heterozygous. P is an uncorrected Pearson's chi-square probability).

###### Gender specific *MTHFR* variants in LHON.

  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131) **:[rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)**   **Total**   **A**   **U**   **P**
  ---------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------- ------- -------
  AA:CC                                                                                                                                          129         50      79      0.137
  AA:CT                                                                                                                                          54          24      30      1
  AA:TT                                                                                                                                          12          7       5       0.381
  CA:CC                                                                                                                                          109         48      61      1
  CA:CT                                                                                                                                          52          26      26      0.372
  CA:TT                                                                                                                                          19          4       15      0.056
  CC:CC                                                                                                                                          26          15      11      0.157
  CC:CT                                                                                                                                          10          6       4       0.345
  CC:TT                                                                                                                                          3           2       1       0.584
  Total                                                                                                                                          414         182     232     

Comparison of c.677C\>T and c.1298A\>C (rs1801133:rs1801131) compound genotypes between LHON patients (A) and controls (C). P is an uncorrected Pearson's chi-square probability).

###### LHON mutation specific *MTHFR* variation

  **Allele**                                                                   **3460**   **11778**   **14484**   **Other**                                             
  ----------------------------------------------------------------------- ---- ---------- ----------- ----------- ----------- ----- ------- ---- ---- ------- ---- ---- -------
  [rs45438591](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45438591)   WT   32         47          0.231       118         149   0.333   8    8    1       12   16   0.393
  HET                                                                     1    0                      6           4                 1       1         0       1         
  MT                                                                      0    0                      0           0                 0       0         0       0         
  [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)     WT   24         33          0.224       74          104   0.199   7    7    1       8    7    0.082
  HET                                                                     10   12                     43          38                2       2         1       8         
  MT                                                                      0    4                      10          15                0       0         3       2         
  [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736)   WT   31         34          0.018       83          118   0.166   1    6    0.028   12   14   0.124
  HET                                                                     3    15                     41          35                6       1         0       3         
  MT                                                                      0    0                      1           1                 2       2         0       0         
  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131)     WT   15         26          0.395       58          71    0.365   5    5    1       3    10   0.129
  HET                                                                     14   20                     52          71                4       4         8       7         
  MT                                                                      2    3                      17          13                0       0         1       0         
  [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976)     WT   27         41          0.624       111         143   0.13    4    7    0.148   9    16   0.141
  HET                                                                     5    6                      15          10                2       2         3       1         
  MT                                                                      2    1                      0           2                 0       3         0       0         
  [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219)   WT   32         48          0.356       124         149   0.383   9    8    0.303   12   16   0.393
  HET                                                                     0    0                      2           7                 0       1         0       1         
  MT                                                                      2    1                      1           1                 0       0         0       0         
  **Genotype**                                                                                                                                                          
  [rs45438591](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45438591)   WT   65         94          0.413       242         302   0.355   17   17   1       24   33   1
  MT                                                                      1    0                      6           4                 1       1         0       1         
  [rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)     WT   58         78          0.415       191         246   0.423   16   16   1       17   22   0.778
  MT                                                                      10   20                     63          68                2       2         7       12        
  [rs45571736](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=45571736)   WT   65         83          0.04        207         271   0.09    8    13   0.176   24   31   0.26
  MT                                                                      3    15                     43          37                10      5         0       3         
  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131)     WT   44         72          0.856       168         213   0.528   14   14   1       14   27   0.142
  MT                                                                      18   26                     86          97                4       4         10      7         
  [rs2274976](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2274976)     WT   59         88          0.436       237         296   0.451   10   16   0.438   21   33   0.297
  MT                                                                      9    8                      15          14                2       8         3       1         
  [rs35737219](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35737219)   WT   64         96          0.228       250         305   0.402   18   17   1       24   33   1
  MT                                                                      4    2                      4           9                 0       1         0       1         

Comparison of LHON mutation specific *MTHFR* variant genotype and allele frequencies between LHON patients (A) and controls (C) where WT and MT are homozygous wild-type and mutant respectively and Het is heterozygous. P is an uncorrected Pearson's chi-square probability.

When combining complex SNPs into complex genotypes we found no association to a compound genotype of c.677C\>T and c.1298A\>C ([rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133):[rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131); [Table 4](#t4){ref-type="table"}). We also performed six locus haplotyping analysis. There was no significant difference in the frequency of each genotype between affected and unaffected.

###### c.677C\>T and c.1298A\>C complex genotypes in LHON

  [rs1801131](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801131) **:[rs1801133](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1801133)**   **Total**   **A**   **U**   **P**
  ---------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------- ------- -------
  AA:CC                                                                                                                                          130         50      79      0.137
  AA:CT                                                                                                                                          54          24      30      1
  AA:TT                                                                                                                                          12          7       5       0.381
  CA:CC                                                                                                                                          109         48      61      1
  CA:CT                                                                                                                                          52          26      26      0.372
  CA:TT                                                                                                                                          19          4       15      0.056
  CC:CC                                                                                                                                          26          15      11      0.157
  CC:CT                                                                                                                                          10          6       4       0.345
  CC:TT                                                                                                                                          3           2       1       0.584
  Total                                                                                                                                          415         182     232     

Comparison of c.677C\>T and c.1298A\>C (rs1801133:rs1801131) compound genotypes between LHON patients (A) and controls (C). P is an uncorrected Pearson's chi-square probability).

Discussion
==========

We found no statistically robust association between any of the 12 functional *MTHFR* SNPs, individually or as complex genotypes, and vision failure in LHON families, or when affected individuals were compared to controls. It is intriguing that specific SNPs appeared to be associated with vision failure when considered in subgroup analyses separating the different LHON mtDNA mutations and different genders, but these associations did not stand up to the rigors of a correction for multiple significance testing. We therefore interpreted our findings conservatively, but larger studies may show that these associations are pathophysiologically relevant. Although we cannot exclude the possibility that *MTHFR* contributes to the pathophysiology of LHON, our findings indicate that the gene is unlikely to be the major nuclear genetic modifier interacting with the primary mtDNA mutations. Genes encoding other enzymes involved in folate metabolism may be relevant, as could dietary intake of folate. Biochemical and epidemiological studies would address these issues. Further genetic studies on a genome-wide level are required to define the nuclear-mitochondrial interaction in LHON.
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